On June 5, 2026 Vcare Pharmatech reported NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.4-5

Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits

Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety.

Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.6

In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients.

Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups.

New Hope for Patients with NTRK Fusion Resistance

As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors.

(Press release, Jiangsu Vcare PharmaTech, JUN 5, 2026, View Source [SID1234666468])

On June 5, 2026 Nerviano Medical Sciences S.r.l. ("NMS"), a global oncology-focused biopharmaceutical company, reported its participation in the upcoming Annual Congress of the European Association for Cancer Research (EACR), taking place in Budapest, Hungary, from June 8 to 11, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

At the meeting, NMS will present a scientific poster featuring its proprietary dual PERK/GCN2 inhibitor, NMS-812.

Title: "NMS-812, a clinical stage dual PERK and GCN2 modulator, with activity in Multiple Myeloma, AML and solid tumors" (Poster EACR26-0678)

Presenter: Claudia Perrera, Head of Biology at NMS

Poster Section: "Experimental / Molecular Therapeutics, Pharmacogenomics"

Poster Board Number: P-355

Date & Time: Tuesday, 09 June 2026 from 10:30 to 20:00 CET

Link to full poster abstract: NMS POSTER SESSION – Tuesday – EACR Congress

This study presents NMS-812, a potent first-in-class clinical-stage dual PERK/GCN2 inhibitor that disrupts tumor stress-response survival pathways, demonstrating single-agent and combination antitumor activity across multiple myeloma, AML, and solid tumor models, including immune-mediated effects, supporting its ongoing Phase 1 AML development and potential expansion into solid tumors.

We look forward to engaging with the scientific community at EACR 2026 and sharing insights from our work.

(Press release, Nerviano Medical Sciences, JUN 5, 2026, View Source [SID1234666467])

On June 5, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported results from an independent market landscape assessment evaluating Annamycin in relapsed/refractory acute myeloid leukemia (R/R AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research demonstrated strong physician interest in Annamycin, with oncologists reporting an average likelihood-to-prescribe score of 6 out of 7. Physicians cited Annamycin’s reported complete remission rates, MRD-negative responses, potential to bridge patients to bone marrow transplant, biomarker-agnostic applicability and reduced cardiotoxicity as key factors supporting potential adoption.

The study included perspectives from academic and community hematologist-oncologists, medical oncologists and pediatric AML specialists. Respondents consistently identified significant unmet need in R/R AML, particularly for patients without actionable mutations and those who relapse or progress following venetoclax-based therapy. Separately, interviews with hospital administrators and insurers revealed that payers view Annamycin as a potentially meaningful value proposition, driven by its efficacy and safety profile and applicability to a broad patient population.

"These independent research findings are highly encouraging and reinforce the potential role we believe Annamycin can play in addressing one of the most difficult areas of AML treatment," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin Biotech. "A physician likelihood to use score of 6 out of 7 reflects meaningful enthusiasm from clinicians who treat AML patients every day. Importantly, the research highlights that physicians recognize that Annamycin is capable of delivering powerful efficacy, producing deep remissions that position patients for transplant and serving a broader population beyond narrow biomarker-defined subsets. Physicians also recognized Annamycin’s safety profile, with the potential for repeat dosing due to the absence of cardiotoxicity."

Key Research Findings

The independent market assessment found that:

Hematologist-oncologists reported an average likelihood to prescribe Annamycin of 6 out of 7.
Physicians expressed strong interest in Annamycin’s reported complete remission and MRD-negative remission profile.
Respondents viewed Annamycin’s potential to bridge patients to bone marrow transplant as a meaningful clinical advantage.
Biomarker-agnostic applicability was viewed as highly relevant given the limitations of mutation-targeted therapies, and physicians noted the potential to combine targeted therapies with Annamycin.
Reduced cardiotoxicity was identified as an important differentiator, providing the possibility for repeat dosing, particularly given the known cardiac limitations of traditional anthracyclines.
Pediatric AML specialists viewed reduced cardiotoxicity as especially meaningful due to long-term survivorship concerns.
Payers indicated that Annamycin’s efficacy profile, safety characteristics and broad applicability could support a compelling value proposition.
Significant Unmet Need Remains in R/R AML

Despite recent progress in targeted therapies, respondents reported that the R/R AML treatment landscape remains fundamentally underserved. Physicians noted that targeted therapies have improved treatment for select biomarker-defined patient groups, but many patients still lack effective options, particularly following venetoclax failure or in the absence of actionable mutations.

Durable remission, improved survival and successful transition to potentially curative transplant were consistently identified as the most important treatment goals.

Annamycin Profile Resonates Across Stakeholders

Across respondent groups, Annamycin generated strong interest due to its reported efficacy profile and potential applicability across a broad R/R AML population. Physicians responded favorably to the combination of deep responses, transplant-enabling potential, broad use independent of mutation status and reduced cardiotoxicity.

The research also found that clinicians viewed Annamycin as a differentiated approach that may preserve the established anti-leukemic activity of the anthracycline class while reducing one of the class’s most significant historical limitations.

"We believe the findings provide important third-party validation of both the clinical and commercial potential of Annamycin," added Mr. Klemp. "As we continue advancing Annamycin, our focus remains on developing a therapy that may address meaningful unmet needs for AML patients, physicians and healthcare systems."

(Press release, Moleculin, JUN 5, 2026, View Source [SID1234666466])

On June 5, 2026 GlyTherix reported the grant of a Canadian patent covering its antibody-drug conjugate (ADC) technology, marking another important milestone in the expansion of the company’s global intellectual property portfolio.
The Canadian patent strengthens protection for GlyTherix’s proprietary ADC platform in a strategically important market and reinforces the company’s commitment to building a robust international patent estate around its innovative oncology programs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With this latest grant, GlyTherix continues to advance the global protection of its technology, enhancing the long-term value of its ADC assets and supporting future development and partnering opportunities.

Strong intellectual property protection is a critical component of successful drug development, and the Canadian patent provides further validation of the novelty and potential of GlyTherix’s targeted cancer therapy approach.

The continued expansion of GlyTherix’s patent portfolio positions GlyTherix to maximise the impact and commercial potential of its technology for patients and stakeholders worldwide.

(Press release, Glytherix, JUN 5, 2026, View Source [SID1234666465])

On June 4, 2026 Oncovita, a French biotech company specialized in therapeutic and prophylactic vaccines, reported that the full preclinical pharmacology package of its lead candidate MVdeltaC which supports the entry into clinics will be presented at the European Association for Cancer Research annual congress (EACR-2026) to be held in Budapest, Hungary on June 08-11, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MVdeltaC is a genetically modified measles virus, one of the Oncovita candidates based on its proprietary technology platform Measovir, derived from the safe and highly immunogenic measles attenuated vaccine virus, a technology which has been previously used successfully for the development of several prophylactic vaccines.

Pr. Frédéric Tangy, CSO and Jean-François Le Bigot PhD, Executive President will present a poster (N° P-402) titled: « In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I dependent tumor clearance and immune memory".

This presentation will include results obtained from in vitro and in vivo models of solid tumor, including PDX models and syngeneic models in immunocompetent mice, such as mesothelioma, bladder, TNBC and neuroblastoma.

MVdeltaC exhibits a very strong immunogenic apoptosis activity resulting in tumor regression and up to total disappearance of the tumors in immunocompetent models (corresponding to RECIST CR Complete Remission). In addition, when animals which completely rejected tumor were re-challenged with tumor cells, no tumor growth was observed, demonstrating antitumor immune protection.

Detailed investigations of the biological MOA allow to conclude to the activation of RIG-I receptor by the defective viral RNA molecules massively generated by the modified measles virus which results in strong innate and adaptive immune activation against the tumors.

Finally, an investigation using IA, in collaboration with Infinitusbio.AI, concludes that MVdeltaC has more impact than MV on 70% of the 104 cancer biomarkers.

MVdeltaC has been granted the Orphan Drug Status by the US-FDA and the EMA for mesothelioma use.

"We look forward to meeting with colleagues and experts at the EACR congress and sharing the positive results gained with MVdeltaC" said Frédéric Tangy, Scientific Director.

"We are now preparing the GMP batch production of this first candidate in an internationally recognized CDMO in order to initiate clinical trial by end of 2027. With the benefit from the ODD status, we could establish a clinical development plan leading to registration while already initiating discussions with VCs and with potential pharma-biotech partners" concluded Jean-François Le Bigot, Executive Chairman of Oncovita.

(Press release, Oncovita, JUN 4, 2026, View Source [SID1234666472])